News | July 12, 2025
Briefs: Emcure Pharmaceuticals and Gland Pharma
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
It is intended for contrast enhancement in MRI scans
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The closing of the Block Acquisition is now expected to be completed by Q3 2025
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Alkem Medtech to acquire 100% stake of Bombay Ortho
Subscribe To Our Newsletter & Stay Updated
